- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06259136
Palliative Care Yields Cancer Wellbeing Support (Pal-Cycles)
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital.
The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care.
Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study described in this protocol, a stepped wedge clinical trial, is part of a larger research project named: The Palliative Care Yields Cancer Wellbeing Support Programme (Pal-Cycles). The aim is to test and evaluate the implementation of the Pal-Cycles intervention, by implementing it in 14 care setting across seven European countries (the Netherlands, Germany, United Kingdom, Poland, Hungary, Romania and Portugal.) The primary focus of the evaluation will be on measuring the effect of the Pal Cycles intervention using the number of patients being readmitted into hospital after they had transferred to community care in comparison with patients receiving usual care. Additional relevant outcomes will also be gathered and analysed such as: the patient's quality of life, the experience from the family carer and the experience from the healthcare professional. Finally, an economic analysis will be embedded in the stepped wedge design.
The goals of the overarching research project are as follows:
- To develop, implement and evaluate a transitional palliative cancer care intervention, with an intervention (the Pal-Cycles intervention) that aims for a smooth transition from the hospital to community-based care in the final months of life.
- Adaptation of the transitional palliative cancer care intervention for patients with advanced cancer for its implementation in seven European countries within the project.
- Training of oncologists in identifying patients with palliative care needs, establishing collaboratively comprehensive treatment and care plans, delivering patient-centred communication around discharge planning, advance care planning, and end-of-life care.
- A clinical trial using a stepped wedge design will be implemented in fourteen care settingsacross seven European countries.
- An implementation support intervention will guide the implementation of the clinical trial in all settings and will investigate barriers and opportunities for implementation and provide tailormade solutions where needed.
- Dissemination of project results.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pippa van den Brand, MSC
- Phone Number: 024 361 1111
- Email: pippa.vandenbrand@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525GA
- Radboudumc
-
Contact:
- Pippa J. van den Brand, Msc
- Phone Number: +31 0643478851
- Email: pippa.vandenbrand@radboudumc.nl
-
Contact:
- Ian Koper, PhD
- Email: ian.koper@radboudumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 18 years or above
- Patients diagnosed with advanced cancer
- Patients that are expected to develop or already may have palliative care needs
- Patients who are in transition from curative (hospital) to palliative care (community care)
Exclusion Criteria:
- People with cancer unable or unwilling to provide consent to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pal-Cycles Intervention
The patients in the intervention arm will be exposed to the Pal-Cycles intervention.
|
The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient.
The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan.
Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
Other Names:
|
No Intervention: Care as usual
The patients included in this intervention will be given care as usual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in number of readmissions into hospital between the patients in the intervention arm and controle arm
Time Frame: 90 days after the end of the study or after death.
|
The primary outcome of this research project will be the difference between the readmission rate from the control group and the intervention group.
This was chosen based on the presumption that if the communication between healthcare professionals improves, the transition to home will be better and patients will be less likely to require hospital care.
Another advantage is that it is a feasible and often well documented outcome measure which can be retrieved across multiple sites in multiple countries.
A second advantage especially relevant for studies concerned with palliative care patients is that it can be measured early, as many patients die (of unrelated causes) during the study.
By measuring early measurement compliance can be ensured.
|
90 days after the end of the study or after death.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic characteristics relative
Time Frame: 14 days after baseline.
|
In order to gain some background on which relative is filling in the FAMCARE, the relative will also be asked some demographic questions concerning their age, gender and relationship to patient.
|
14 days after baseline.
|
Place and date of death
Time Frame: 90 days after the end of the study or after death.
|
90 days after the end of the study or after death.
|
|
Presence of Advance decisions to refuse treatment (ADRTs) and Advance care plans (ACPs) as referred to in the hospital medical records.
Time Frame: 90 days after the end of the study or after death.
|
90 days after the end of the study or after death.
|
|
Referrals to palliative care services
Time Frame: 90 days after the end of the study or after death.
|
90 days after the end of the study or after death.
|
|
Economic analysis to assess the consequences of the intervention on health outcomes and resource utilization
Time Frame: 90 days after the end of the study or after death.
|
90 days after the end of the study or after death.
|
|
Demographic characteristics patients
Time Frame: Baseline.
|
The demographic characteristics of the patient will be asked in a questionnaire.
In addition to participating in the stepped wedge clinical trial described in this research protocol, they are also the co-lead on work package 5.
This work package has as objective to analyse whether certain "sensitive" characteristics have influenced the quality of care of the patient during the oncology treatment.
To limit patient burden the demographic characteristics in the questionnaire such as gender, age, civil status and members of the household will also be used as background information for the stepped wedge clinical trial.
|
Baseline.
|
European Organization for Research and Treatment for Cancer Quality of Life Questionnaire C30
Time Frame: Baseline, 30 days and 90 days after baseline.
|
In addition to the number of admissions, another important indicator for the effectiveness of the Pal-Cycles interventions is the quality of life of life.
To measure this multiple questionnaires will be used.
One of them being the EORTC QLQ-C30.
The questionnaire comprises of 30 questions assessing the patients ability to function from a physical, emotional, cognitive and functional point of view.
For 28 of the questions the response can be given via a four point Likert scale giving the options: not at all, a little, quite a bit, very much.
Where 1, not at all, indicates a higher score than 4, very much.
The last two questions can be responded to via a visual analogue scale from 1 to7 (poor to excellent).
Where 7, excellent, indicates a higher score than than 1, poor.
|
Baseline, 30 days and 90 days after baseline.
|
The Functional Assessment of Cancer Therapy - General (FACT-G)
Time Frame: Baseline, 30 days and 90 days after baseline.
|
The other questionnaire that will be used to measure the patients quality of life is the FACT-G.
The FACT-G was specifically developed to measure the cancer patient's health-related quality of life.
This questionnaire for current and former cancer patients, is made up of 27 questions regarding quality of life by assessing wellbeing in four domains: physical, emotional, cognitive and functional.
To all questions can be responded by filling in a 5 point likert scale; not at all, a little bit, somewhat, quite a bit and very much.
Where 0, not at all, indicates a better score than 4, very much.
|
Baseline, 30 days and 90 days after baseline.
|
The Consultation and Rational Empathy measure (The CARE measure)
Time Frame: 14 days after baseline
|
Another important outcome measure for this study is whether or not the Pal-Cycles intervention improves the quality of care. A key part of the Pal-Cycles intervention is the conversation between the clinician and the patient where the transition from curative oncological care to palliative care is discussed. To evaluate this conversation the CARE measure was included in the study. This questionnaire consists of ten Likert scale questions in which the emotional, ethical, cognitive and behavioural elements of the consultation. The patients can respond to the questionnaire by using a five point Likert scale consisting of the following options: 1 poor,2 fair, good,3 very good, 4 excellent. Where 4 excellent is indicating a better conversation than 3 very good. |
14 days after baseline
|
Caregiver Network Analysis
Time Frame: 30 days after baseline
|
The Caregiver Network Analysis was developed based on existing literature during a previous European project Insup-c for the purposes of a care network analysis.
In the current project the objective is to improve the transition from curative care at the hospital to palliative care at home by ameliorating the communication between healthcare professionals.
The questionnaire could assist in establishing if this is effective.
The caregiver network analysis consists of twelve questions about which healthcare providers the patient has contact with as well as how the patient perceives their level of cooperation and quality of care.
The answer options vary from dichotomous answer categories and open ended answers to 5- point Likert scales which have a range from 0 to 4.
Where 4 , strongly agree, indicates a better score than 0 strongly disagree.
|
30 days after baseline
|
FAMCARE
Time Frame: 14 days after baseline
|
Family carers play a large role in caring for patients with palliative care needs.
There is an international trend to reduce hospital admission days and stimulate, community care, in order to decrease healthcare costs, but also to empower patients and their families.
Therefore, measuring the family satisfaction with care has become integral to evaluating the quality of care.
A scale that has proven to be a reliable measurement instrument is the FAMCARE.
It was developed to measure satisfaction on performance of individual care takers performance of family members of patients with advanced cancer.
This questionnaire consists of 20 questions to which can be responded to by a five point Likert scale.
Where 1, very satisfied, indicates a better score than 5, very dissatisfied.
|
14 days after baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jeroen Hasselaar, Radboud University Medical Center (Radboudumc)
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 101057243
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on A transitional palliative care intervention
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
Mayo ClinicCompletedPalliative Care | Transitional CareUnited States
-
University of AarhusAarhus University Hospital; Research Unit for General Practice, Aarhus UniversityWithdrawn
-
Duke UniversityUniversity of North Carolina, Chapel HillCompletedBrain Injuries, Traumatic | Patients | Family Members | Transitional CareUnited States
-
Singapore General HospitalDuke-NUS Graduate Medical School; Agency for Integrated Care, SingaporeCompletedChronic DiseasesSingapore
-
Massachusetts General HospitalAmerican Society of Clinical OncologyCompletedNon-small Cell Lung CancerUnited States
-
Philipps University Marburg Medical CenterAstraZenecaUnknownDepression | Chronic Obstructive Pulmonary Disease | End-of-Life Fear | Fear About Death and DyingGermany
-
McMaster UniversityHamilton Health Sciences Corporation; Ontario Ministry of Health and Long Term... and other collaboratorsCompleted
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingCoronary Artery Disease | Ischemic Heart Disease | Congestive Heart Failure | Acute Myocardial Infarction
-
Vanderbilt University Medical CenterActive, not recruiting